diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12757diaendo-12757Research ArticleНовостиNewsВозможности применения фиксированной комбинации алоглиптина и пиоглитазона в условиях современной парадигмы лечения сахарного диабета 2 типаPossibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatmenthttps://orcid.org/0000-0002-5057-127XШестаковаМ. В.ShestakovaM. V.

Шестакова Марина Владимировна - доктор медицинских наук, проф., академик РАН; eLibrary SPIN: 7584-7015.

117036, Москва, ул. Дм. Ульянова, д. 11

Marina V. Shestakova, MD, PhD, Professor; eLibrary SPIN: 7584-7015.

11 Dm. Ulyanova str., Moscow, 117036

nephro@endocrincentr.ruhttps://orcid.org/0000-0002-9944-2997АнциферовМ. Бо.AntsiferovM. B.

Анциферов Михаил Борисович - доктор медицинских наук, профессор; eLibrary SPIN: 1035-4773

Москва

Mikhail B. Antsiferov, MD, PhD, Professor; eLibrary SPIN: 1035-4773.

Moscow

antsiferov@rambler.ruhttps://orcid.org/0000-0002-7936-7619АметовА. С.AmetovA. S.

Alexander S. Ametov, MD, PhD, Professor; eLibrary SPIN: 9511-1413.

Moscow

Alexander S. Ametov, MD, PhD, Professor; eLibrary SPIN: 9511-1413.

Moscow

alexander.ametov@gmail.comhttps://orcid.org/0000-0001-6581-4521ГалстянГ. Р.GalstyanG. R.

Gagik R. Galstyan, MD, PhD, Professor; eLibrary SPIN: 9815-7509.

Moscow

Gagik R. Galstyan, MD, PhD, Professor; eLibrary SPIN: 9815-7509.

Moscow

galstyangagik964@gmail.comДемидоваТ. Ю.DemidovaT. Y.

Tatiana Y. Demidova, MD, PhD, Professor;Researcher ID: D-3425-2018; Author ID: 7003771623; eLibrary SPIN: 9600-9796

Moscow

Tatiana Y. Demidova, MD, PhD, Professor; Researcher ID: D-3425-2018; Author ID: 7003771623; eLibrary SPIN: 9600-9796

Moscow

t.y.demidova@gmail.comhttps://orcid.org/0000-0003-1316-5245МкртумянА. М.MkrtumyanA. M.

Ashot M. Mkrtumyan, MD, PhD, Professor; Author ID: 513441; eLibrary SPIN: 1980-8700.

Moscow

Ashot M. Mkrtumyan, MD, PhD, Professor; Author ID: 513441; eLibrary SPIN: 1980-8700.

Moscow

vagrashot@mail.ruhttps://orcid.org/0000-0001-9390-1200ПетунинаН. А.PetuninaN. A.

Nina A. Petunina, MD, PhD, Professor; eLibrary SPIN: 9784-3616.

Moscow

Nina A. Petunina, MD, PhD, Professor; eLibrary SPIN: 9784-3616.

Moscow

napetunina@mail.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian FederationЭндокринологический диспансер Департамента здравоохранения города МосквыRussian FederationEndocrinology Dispensary of the Moscow Department of HealthRussian FederationРоссийская медицинская академия непрерывного профессионального образованияРоссияRussian Medical Academy of Continuous Professional EducationRussian FederationРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссияThe Russian National Research Medical University named after N.I. PirogovRussian FederationМосковский государственный медико-стоматологический университет имени А.И. ЕвдокимоваРоссияA.I. Yevdokimov Moscow State University of Medicine and DentistryRussian FederationПервый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation202114072021242193197Copyright © Шестакова М.В., Анциферов М.Б., Аметов А.С., Галстян Г.Р., Демидова Т.Ю., Мкртумян А.М., Петунина Н.А., 20212021Шестакова М.В., Анциферов М.Б., Аметов А.С., Галстян Г.Р., Демидова Т.Ю., Мкртумян А.М., Петунина Н.А.Shestakova M.V., Antsiferov M.B., Ametov A.S., Galstyan G.R., Demidova T.Y., Mkrtumyan A.M., Petunina N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12757

В основе гипергликемии при сахарном диабете 2 типа (СД2) лежат три основных механизма: инсулинорезистентность, прогрессирующая дисфункция β-клеток и избыточная продукция глюкозы печенью. Манифестации СД2, как правило, предшествует длительный период инсулинорезистентности. Назначение сахароснижающих препаратов, воздействующих на разные звенья патогенеза, обеспечивает эффективное устойчивое снижение гликемии. На сегодняшний день в клинической практике используются разные комбинации сахароснижающих препаратов, выбор которых определяется особенностями течения диабета у пациента, наличием сопутствующих заболеваний и осложнений диабета, а также доминирующей клинической проблемой. В настоящей резолюции представлено заключение совета экспертов по возможности применения комбинации алоглиптина и пиоглитазона у пациентов с СД2.

Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.

The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, reducing a steady decrease in glycemia. To date, in clinical practice, various combinations of hypoglycemic drugs are used, the choice of which is determined by the characteristics of the course of diabetes in the patient, the presence of concomitant diseases and complications of diabetes, as well as the dominant clinical problem. This resolution provides an expert council opinion on the feasibility of using a combination of alogliptin and pioglitazone in patients with type 2 diabetes.

сахарный диабеталоглиптинпиоглитазонфиксированная комбинацияdiabetes mellitusalogliptinpioglitazonefixed combinationСовет экспертов, результаты которого легли в основу этой статьи, проводился при поддержке АО «Нижфарм»ReferencesShestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes epidemiology in Russia: What has changed over the decade? Ter Arkh. 2019;91(10):4-13. doi: https://doi.org/10.26442/00403660.2019.10.000364Shestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes epidemiology in Russia: What has changed over the decade? Ter Arkh. 2019;91(10):4-13. doi: https://doi.org/10.26442/00403660.2019.10.000364Waugh J, Keating GM, Plosker GL, et al. Pioglitazone: A review of its use in type 2 diabetes mellitus. Drugs. 2006;66(1):85-109. doi: https://doi.org/10.2165/00003495-200666010-00005Waugh J, Keating GM, Plosker GL, et al. Pioglitazone: A review of its use in type 2 diabetes mellitus. Drugs. 2006;66(1):85-109. doi: https://doi.org/10.2165/00003495-200666010-00005Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом: Клинические рекомендации (Вып. 9) // Сахарный диабет. — 2019. — Т. 22. — №S1. — С. 1-144. doi: https://doi.org/10.14341/DM221S1Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.). doi: https://doi.org/10.14341/DM221S1Tan MH, Baksi А, Krahulec В, et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28(3):544-550. doi: https://doi.org/10.2337/diacare.28.3.544.Tan MH, Baksi А, Krahulec В, et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28(3):544-550. doi: https://doi.org/10.2337/diacare.28.3.544.Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. doi: https://doi.org/10.1016/S0140-6736(05)67528-9.Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. doi: https://doi.org/10.1016/S0140-6736(05)67528-9.Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007;50(10):2297-2300. doi: https://doi.org/10.1021/jm070104lFeng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007;50(10):2297-2300. doi: https://doi.org/10.1021/jm070104lErdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49(17):1772-1780. doi: https://doi.org/10.1016/j.jacc.2006.12.048Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49(17):1772-1780. doi: https://doi.org/10.1016/j.jacc.2006.12.048Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspectivepioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38(3):865-73. doi: https://doi.org/10.1161/01.STR.0000257974.06317.49Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspectivepioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38(3):865-73. doi: https://doi.org/10.1161/01.STR.0000257974.06317.49Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. J Am Med Assoc. 2007;298(10):1180-1188. doi: https://doi.org/10.1001/jama.298.10.1180Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. J Am Med Assoc. 2007;298(10):1180-1188. doi: https://doi.org/10.1001/jama.298.10.1180Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016;374(14):1321-1331. doi: https://doi.org/10.1056/NEJMoa1506930.Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016;374(14):1321-1331. doi: https://doi.org/10.1056/NEJMoa1506930.Young LH, Viscoli CM, Curtis JP, et al. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. Circulation. 2017;135(20):1882-1893. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.024863Young LH, Viscoli CM, Curtis JP, et al. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. Circulation. 2017;135(20):1882-1893. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.024863Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129-1136. doi: https://doi.org/10.1016/S0140-6736(07)61514-1.Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129-1136. doi: https://doi.org/10.1016/S0140-6736(07)61514-1.Eldor R, DeFronzo RA, Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: Glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care. 2013;36(2):S162. doi: https://doi.org/10.2337/dcS13-2003Eldor R, DeFronzo RA, Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: Glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care. 2013;36(2):S162. doi: https://doi.org/10.2337/dcS13-2003Clarke GD, Solis-Herrera C, Molina-Wilkins M, et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes Care. 2017;40(11):1530-1536. doi: https://doi.org/10.2337/dc17-0078Clarke GD, Solis-Herrera C, Molina-Wilkins M, et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes Care. 2017;40(11):1530-1536. doi: https://doi.org/10.2337/dc17-0078Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406-2408. doi: https://doi.org/10.2337/dc10-0159Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406-2408. doi: https://doi.org/10.2337/dc10-0159Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes, Obes Metab. 2011;13(12):1088-1096. doi: https://doi.org/10.1111/j.1463-1326.2011.01463.xBosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes, Obes Metab. 2011;13(12):1088-1096. doi: https://doi.org/10.1111/j.1463-1326.2011.01463.xDeFronzo RA, Burant CF, Fleck P, et al. Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes. J Clin Endocrinol Metab. 2012;97(5):1615-1622. doi: https://doi.org/10.1210/jc.2011-2243DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes. J Clin Endocrinol Metab. 2012;97(5):1615-1622. doi: https://doi.org/10.1210/jc.2011-2243Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565-574. doi: https://doi.org/10.1530/EJE-13-0639Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565-574. doi: https://doi.org/10.1530/EJE-13-0639

The authors declare that there are no conflicts of interest present.